Cellectar Biosciences (FRA:NV4) ROCE % : -2,318.79% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cellectar Biosciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -2,318.79%.

Cellectar Biosciences ROCE % Historical Data

The historical data trend for Cellectar Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences ROCE % Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-125.48

-46.70

-57.19

-122.10

-497.18

Cellectar Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-199.52	-288.76	-825.23	-1,464.20	-2,318.79

Cellectar Biosciences ROCE % Calculation

Cellectar Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-35.727	/	( ( (20.381 - 5.219)	+	(11.074 - 11.864) )	/ 2 )
	=	-35.727	/	( (15.162	+	-0.79)	/ 2 )
	=	-35.727	/	7.186
	=	-497.18 %

Cellectar Biosciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-46.028	/	( ( (20.193 - 15.433)	+	(11.074 - 11.864) )	/ 2 )
	=	-46.028	/	( ( 4.76	+	-0.79 )	/ 2 )
	=	-46.028	/	1.985
	=	-2,318.79 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cellectar Biosciences (FRA:NV4) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cellectar Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (FRA:NV4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLRB:USA

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines